Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Genmont Biotech Incorporation currently has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. This portfolio of 3 pending actions reflects the company's active efforts to secure patent rights for its biotechnological and pharmaceutical innovations. The focus on Biotechnology & Pharmaceuticals is central to its current intellectual property strategy, aiming to protect its specialized research and development in the life sciences sector.
The prosecution is distributed among 3 distinct examiners and 2 distinct art units. Since there are 3 pending office actions and 3 distinct examiners, each case is being handled by a different individual at the patent office. The involvement of 2 distinct art units suggests that these 3 distinct examiners are working within a narrow range of specialized departments, which may lead to some consistency in examination standards and procedural requirements.
DAVIS, RUTH A is the busiest examiner for the portfolio, with 1 busiest examiner pending action. Because the busiest examiner pending count is 1 and there are 3 total pending office actions, the workload is evenly spread across all 3 distinct examiners. This distribution across 2 distinct art units requires the company to manage three separate examiner relationships while adhering to the standards of two specialized departments to advance its 3 total pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, RUTH A | 1 | 60.8% | +31.1% |
| NIEBAUER, RONALD T | 1 | 40.8% | +34.0% |
| DURYEE, ALEXANDER MARSH | 1 | 33.3% | +41.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17862766 | COMPOSITION WITH LACTOBACILLUS PARACASEI AND A METHOD TO TREAT NASOPHARYNGEAL CARCINOMA THROUGH PYROPTOSIS OR CELL CYCLE ARREST | DURYEE, ALEXANDER MARSH | 37d overdue |
| 19562301 | USE OF NUCLEOTIDE OF LACTOBACILLUS FERMENTUM GM-090 FOR PREPARING PHARMACEUTICAL COMPOSITION FOR REGULATING IMMUNITY | DAVIS, RUTH A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17862766 | COMPOSITION WITH LACTOBACILLUS PARACASEI AND A METHOD TO TREAT NASOPHARYNGEAL CARCINOMA THROUGH PYROPTOSIS OR CELL CYCLE ARREST | DURYEE, ALEXANDER MARSH | 37d overdue |
| 19562301 | USE OF NUCLEOTIDE OF LACTOBACILLUS FERMENTUM GM-090 FOR PREPARING PHARMACEUTICAL COMPOSITION FOR REGULATING IMMUNITY | DAVIS, RUTH A | — |
| 18585638 | USE OF LACTOBACILLUS PARACASEI GM-080 AND PEPTIDES THEREOF FOR ANTIMICROBIA | NIEBAUER, RONALD T | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19562301 | USE OF NUCLEOTIDE OF LACTOBACILLUS FERMENTUM GM-090 FOR PREPARING PHARMACEUTICAL COMPOSITION FOR REGULATING IMMUNITY | DAVIS, RUTH A | 1699 | §102§112Other | Non-Final OA | — | Pending | Mar 10, 2026 |
| 18585638 | USE OF LACTOBACILLUS PARACASEI GM-080 AND PEPTIDES THEREOF FOR ANTIMICROBIA | NIEBAUER, RONALD T | — | §102§103§112DP | Non-Final OA | — | Pending | Feb 23, 2024 |
| 17862766 | COMPOSITION WITH LACTOBACILLUS PARACASEI AND A METHOD TO TREAT NASOPHARYNGEAL CARCINOMA THROUGH PYROPTOSIS OR CELL CYCLE ARREST | DURYEE, ALEXANDER MARSH | 1657 | §103§112 | Non-Final OA | 37d overdue | Pending | Jul 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial